Orexo: Zubsolv Rx Data week 5, 2017

According to latest Symphony Health Solutions Rx data, Zubsolv tablets showed a market share of 5.61% (5.58%), 4-week rolling average. The total number of Zubsolv tablets sold week 5 (4) reaching 321,704 (309,501). Zubsolv prescriptions (TRx) recorded a market share of 5.59% (5.57%), 4-week rolling average. Total number of prescriptions reaching 11,777 (11,424) during the week. The overall market (buprenorphine/naloxone) showed a y/y growth rate of 8.9% (7.8%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 10.4% (8.9%) (4-week rolling average).

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-03-24 Update
2017-03-22 Analys
2017-03-21 Update
2017-03-21 Update
2017-03-17 Update
2017-03-16 Update
2017-03-14 Update
2017-03-14 Update
2017-03-10 Update
2017-03-10 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-06 Update
2017-03-06 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-01 Update
2017-02-28 Update
2017-02-27 Update
2017-02-27 Update
2017-02-27 Update